This Pharma Stock Zooms 5% On Strong Q1 Results, Strategic Acquisition Plan

Shares of Sudarshan Pharma Industries Ltd gained 4.64 per cent on Monday, reaching Rs 32.50 apiece against the previous close of Rs 31.06. Trading volumes on the BSE spiked by more than 1.01 times. The stock has delivered multibagger returns, surging 110 per cent from its 52-week low of Rs 15.51, though it remains below its 52-week high of Rs 53.50. In the preceding twenty-four months, the stock has appreciated 300 per cent, thus rewarding patient, enduring shareholders.

For the first quarter of FY26, the firm recorded robust financial results, with consolidated net sales advancing 46.4 per cent to Rs 145.26 crore year-on-year. The company also achieved a profitable reversal, reporting a net profit of Rs 3.96 crore, in contrast to a net loss of Rs 1.21 crore in the comparable quarter of FY25. For FY25, Sudarshan Pharma reported net sales of Rs 505 crore, up 9 per cent year-on-year, while net profit grew 45 per cent to Rs 16 crore. The company, which has a market capitalisation of Rs 770 crore, has delivered an impressive profit CAGR of 70 per cent over the last five years.

In a significant strategic move, the company's board approved the acquisition of land, building, and plant & machinery from Srigen Lifesciences Pvt Ltd for Rs 25.50 crore. The facility, located in Medchal, Telangana, spans 1,563 square metres and includes an 80 KL reactor capacity. Srigen has developed 50 potential API key starting materials, including patent-protected products. The acquisition, expected to close by December 31, 2025, will be funded entirely in cash and is aimed at boosting Sudarshan Pharma's production capabilities for APIs and chemical products.

Investor sentiment sustained a strongly positive trajectory over the interval under review. In June 2025, foreign institutional purchasers acquired 2.484 million shares, corresponding to a 19.49 per cent augmentation in cumulative foreign holdings when compared to the March benchmark.

Established in 2008 and located in Mumbai, Sudarshan Pharma Industries Ltd has located its core competence across the pharmaceuticals and chemicals interface, dedicating capacity to manufacturing active pharmaceutical ingredients, intermediates, and finished dosage forms, in parallel with the trading of chemicals and solvents. The range features brands identified by the registered "R" trademark, among which Love Birds and Metfocal are prominent examples. Distribution is balanced across domestic and overseas channels, with current export operations directed at Southeast Asia, the Middle East, and North Africa.